Filing Signals

Source: SEC EDGAR Compiled 2026-11-14 10:32 UTC 23 automated checks passing

← All events

Lunai Bioworks Inc.

CIK 1527728 LNAI·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Late filing NT 10-K
  2. Finance chief departure 8-K +24d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Finance chief departure elevated Filing comparison

Lunai Bioworks Inc.'s Chief Financial Officer departed, replaced on an interim basis

Evidence
Interim only
Yes
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
elevated
Source
SEC 8-K item code
Successor named
No
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Late filing elevated Filing comparison

Lunai Bioworks Inc. filed its annual report late and said it expects a significant change in results

expects significant change in results 1 day past the statutory due date.

(the “Company”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended June 30, 2026 (the “Form 10-K”) within the prescribed time period.
Evidence
Anticipates significant change
Yes
Days past due date
1
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
(the “Company”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended June 30, 2026 (the “Form 10-K”) within the prescribed time period.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗